Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Infliximab biobetter - MabPharm

Next Previous
X
Search
Drug Profile

Infliximab biobetter - MabPharm

Alternative Names: CMAB 008; STI-002; TNF2

Latest Information Update: 22 Jun 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mabtech
  • Developer Mabpharm; Shanghai Biomabs Pharmaceuticals
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics; Biobetters
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Ankylosing spondylitis; Crohn's disease; Psoriasis; Rheumatoid arthritis; Ulcerative colitis

Most Recent Events

  • 13 Jun 2023 Taizhou Mabtech Pharmaceutical plans a phase IV post-marketing registry trial for Crohn's disease (In children, In adolescents) in China (Parenteral, Injection) in July 2023 (NCT05906576)
  • 23 Jul 2021 Registered for Ankylosing spondylitis in China (Parenteral)
  • 20 Jul 2021 Registered for Crohn's disease (In children, In adults) in China (Parenteral)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top